Overview

Treatment of Diabetes in Patients With Systolic Heart Failure

Status:
Completed
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
Investigator Initiated Study to study the effects of Canagliflozin 100 milligrams (mg) vs Sitagliptin 100 mg on parameters of aerobic exercise capacity (peak oxygen consumption [VO2]) and ventilator efficiency (minute ventilation [VE]/carbon dioxide production [VCO2] slope) at cardiopulmonary exercise test (CPET) after 12 weeks of active treatment (primary endpoints). Blood pressure (BP), body water content, body composition, cardiac function, and diet will be also measured (secondary endpoints).
Phase:
Phase 4
Details
Lead Sponsor:
Virginia Commonwealth University
Collaborator:
Janssen Scientific Affairs, LLC
Treatments:
Canagliflozin
Sitagliptin Phosphate